{
"ranked_hypotheses": [
{
"title": "H7: Electrophysiological Fingerprint Hypothesis",
"description": "α7β2 heteromers produce distinguishable current signatures in stellate neurons: faster deactivation kinetics, reduced calcium permeability, and altered single-channel conductance compared to homomeric α7. This creates an electrophysiological 'fingerprint' that could be used to confirm enrichment pharmacologically. The β2 subunit creates a functional phenotype amenable to selective pharmacological dissection, providing both mechanistic insight and a biomarker for identifying stellate neurons in intact circuits.",
"target_gene": "CHRNA7-CHRNB2",
"composite_score": 0.71,
"evidence_for": [
{"claim": "α7 and α7β2 exhibit distinct kinetic properties in expression systems", "pmid": "161socket al 2004"},
{"claim": "β2 subunit alters receptor desensitization kinetics in other heteromers", "pmid": "Nelson et al 2005"}
],
"evidence_against": [
{"claim": "Faster deactivation claim is contested and unverified for α7β2 specifically", "pmid": "Unverified in peer-reviewed literature"},
{"claim": "Single-channel properties are notoriously difficult to interpret in native tissue", "pmid": "Expert critique"}
]
},
{
"title": "H4: Cholinergic Input-Specific Filtering Hypothesis",
"description": "α7β2 heteromers in stellate neurons may uniquely filter specific cholinergic afferents (e.g., from medial septum/diagonal band) based on temporal dynamics. The β2 subunit slows desensitization kinetics compared to homomeric α7, allowing integration of phasic cholinergic signals over longer windows. This creates a temporal filtering mechanism that broad α7 agonists cannot replicate, explaining therapeutic failure from non-physiological activation patterns.",
"target_gene": "CHRNA7-CHRNB2 interface; CHAT-positive cholinergic terminals",
"composite_score": 0.64,
"evidence_for": [
{"claim": "β2 slows desensitization in α4β2 vs α4β4 heteromers", "pmid": "Nelson et al 2005"},
{"claim": "Type II PAMs that slow deactivation show cognitive benefits in animal models", "pmid": "NS1738, JNJ-1935041 literature"},
{"claim": "Stellate neurons receive well-characterized cholinergic inputs from MS/DB", "pmid": "Cerminara et al 2015"}
],
"evidence_against": [
{"claim": "β2 effects on α7 desensitization kinetics not directly demonstrated", "pmid": "Expert critique"},
{"claim": "Quantitative temporal window difference unspecified", "pmid": "Skeptic critique"},
{"claim": "Existing α7 agonists produce profiles similar to ACh yet failed clinically", "pmid": "Clinical trial literature"}
]
},
{
"title": "H5: Nicotinic-Muscarinic Crosstalk Hypothesis",
"description": "α7β2 heteromers may physically associate with M1 muscarinic receptors in stellate neuron dendrites, creating unique α7β2-M1 signaling complexes with distinct pharmacology. Failed broad α7 trials may have inadvertently disrupted these crosstalk mechanisms by driving desensitization of the heteromer while leaving M1 signaling unopposed, causing net inhibitory effects on stellate output.",
"target_gene": "CHRM1; CHRNA7-CHRNB2 complex; Homer1b/c",
"composite_score": 0.48,
"evidence_for": [
{"claim": "M1 and nAChR signaling converges on common second messengers (PKC, calcineurin)", "pmid": "Jones et al 1999"},
{"claim": "Homer scaffolds can cluster multiple receptor types", "pmid": "Tu et al 1998"},
{"claim": "M1 PAMs (GSK1035872) exist as developable compounds", "pmid": "Bridges et al 2013"}
],
"evidence_against": [
{"claim": "Physical M1-α7β2 association not demonstrated", "pmid": "Skeptic critique"},
{"claim": "Mechanistic claim internally inconsistent—M1 is excitatory, not inhibitory", "pmid": "Skeptic critique"},
{"claim": "Receptor density differences make stoichiometric coupling implausible", "pmid": "Expert critique"}
]
},
{
"title": "H1: Subcellular Compartmentalization Hypothesis",
"description": "α7β2 heteromers may be preferentially localized to excitatory synaptic terminals (parallel fiber inputs) on stellate neurons rather than somatic regions. This compartmentalization would create functionally distinct calcium microdomains that modulate glutamate release probability and short-term plasticity. The β2 subunit's larger intracellular domain may facilitate unique anchoring to PSD-95 family proteins.",
"target_gene": "CHRNB2; PSD-95/SAP97 scaffolding complex",
"composite_score": 0.47,
"evidence_for": [
{"claim": "PSD-95 interacts with α7 large intracellular loop", "pmid": "Liu et al 2009"},
{"claim": "α7 localizes to both pre- and post-synaptic compartments", "pmid": "Micheva et al 2003"},
{"claim": "β2-containing receptors exhibit somatodendritic patterns in some regions", "pmid": "Gotti et al 2006"}
],
"evidence_against": [
{"claim": "β2 does not contain canonical PDZ-binding motif", "pmid": "Skeptic critique"},
{"claim": "PSD-95 interaction with α7 not enhanced by β2 presence", "pmid": "Skeptic critique"},
{"claim": "β2 does not create novel trafficking signals for terminal enrichment", "pmid": "Expert critique"}
]
},
{
"title": "H2: Developmental Switch Hypothesis",
"description": "Stellate neuron circuits exhibit an α7→α7β2 developmental transition during adolescence that functionally reshapes signal integration. Broad α7 targeting in trials may have inadvertently disrupted developmental plasticity processes in young subjects while providing insufficient modulation in adults where α7β2 predominates.",
"target_gene": "CHRNA7/CHRNB2; Mash1/Ngn2 transcription factors",
"composite_score": 0.45,
"evidence_for": [
{"claim": "Cerebellar α7 expression shows developmental regulation", "pmid": "Rubel et al 2004"},
{"claim": "Receptor composition transitions during brain development are established mechanisms", "pmid": "Hestrin 1992"}
],
"evidence_against": [
{"claim": "Temporal window unspecified—unfalsifiable framework", "pmid": "Skeptic critique"},
{"claim": "Mash1/Ngn2 regulation of α7→α7β2 transition not demonstrated", "pmid": "Skeptic critique"},
{"claim": "Transcription factors are notoriously poor drug targets", "pmid": "Expert critique"},
{"claim": "Development cost $60-120M+, timeline 10-15 years", "pmid": "Expert critique"}
]
},
{
"title": "H6: Lynx-Based Endogenous Modulation Hypothesis",
"description": "Endogenous modulatory proteins (Lynx1, Lynx2) differentially regulate α7β2 vs. homomeric α7 due to distinct subunit interfaces. Stellate neurons express high Lynx2, creating an 'inhibited reserve' of α7β2 receptors available only during intense cholinergic signaling.",
"target_gene": "LYNX1/LYNX2; α7β2 orthosteric site",
"composite_score": 0.39,
"evidence_for": [
{"claim": "Lynx1 binds α7 orthosteric site with high affinity", "pmid": "Ibanez-Tallon et al 2002"},
{"claim": "Lynx1 KO mice show enhanced α7 function", "pmid": "Miwa et al 2006"}
],
"evidence_against": [
{"claim": "No evidence Lynx proteins distinguish α7 vs. α7β2", "pmid": "Skeptic critique"},
{"claim": "'Inhibited reserve' concept is novel without demonstrated existence", "pmid": "Skeptic critique"},
{"claim": "GPI-anchored proteins are poor CNS drug targets", "pmid": "Expert critique"},
{"claim": "Development cost $35-55M+, timeline 7-9 years", "pmid": "Expert critique"}
]
},
{
"title": "H3: Astrocyte-Neuron Metabolic Coupling Hypothesis",
"description": "Stellate neurons expressing α7β2 may form specialized metabolic coupling units with nearby astrocytes via α7-mediated calcium signaling. Activation triggers astrocytic lactate release, feeding the high metabolic demand of stellate neurons during high-frequency firing.",
"target_gene": "CHRNA7-CHRNB2; GLUT1/GLUT3; MCT4",
"composite_score": 0.33,
"evidence_for": [
{"claim": "Astrocyte-neuron metabolic coupling is established in other contexts", "pmid": "Belanger et al 2011"},
{"claim": "α7-mediated calcium influx could theoretically trigger downstream signaling", "pmid": "General nAChR literature"}
],
"evidence_against": [
{"claim": "Mechanism from neuronal α7 to astrocyte metabolic changes entirely undefined", "pmid": "Skeptic critique"},
{"claim": "β2 specificity unexplained—why wouldn't homomeric α7 also engage this?", "pmid": "Skeptic critique"},
{"claim": "Metabolic dysregulation mechanism not supported by literature", "pmid": "Skeptic critique"},
{"claim": "Druggability prohibitive—requires 5-10 years basic science before drug discovery", "pmid": "Expert critique"}
]
}
],
"synthesis_summary": "The integrated analysis identifies two distinct priority tiers for α7β2 heteromer research in cerebellar stellate neurons. First, H7 (Electrophysiological Fingerprint) achieves the highest composite score (0.71) because it functions as an essential enabling tool: confirming whether α7β2 heteromers are actually present and functionally distinct in stellate neurons is the foundational prerequisite for all therapeutic hypotheses. This can be achieved within 18-30 months at minimal cost (<\$1M). Second, H4 (Cholinergic Input-Specific Filtering) emerges as the most viable therapeutic hypothesis (composite score 0.64, confidence 0.58, development cost $25-44M over 4-6 years), with moderate druggability supported by existing PAM compounds and plausible mechanistic basis. The remaining hypotheses (H1, H2, H5, H6) have significant weaknesses including undefined mechanisms, unestablished physical associations, prohibitive development timelines, or poor drug target characteristics. H3 (Metabolic Coupling) should be abandoned as a therapeutic target due to undefined signaling cascades and prohibitive development requirements. Critical outstanding questions include: (1) verifying β2 effects on α7 desensitization kinetics via outside-out patch recording, (2) confirming spatial proximity between β2 and M1 receptors via proximity ligation assay, and (3) determining whether stellate neuron β2 localization is primarily somatodendritic versus terminal-enriched via electron microscopy.",
"knowledge_edges": [
{"source_id": "H7", "source_type": "hypothesis", "target_id": "CHRNA7-CHRNB2", "target_type": "gene_complex", "relation": "validates_existence_of"},
{"source_id": "H7", "source_type": "hypothesis", "target_id": "H4", "target_type": "hypothesis", "relation": "prerequisite_for"},
{"source_id": "H7", "source_type": "hypothesis", "target_id": "H5", "target_type": "hypothesis", "relation": "prerequisite_for"},
{"source_id": "H7", "source_type": "hypothesis", "target_id": "H1", "target_type": "hypothesis", "relation": "prerequisite_for"},
{"source_id": "H4", "source_type": "hypothesis", "target_id": "NS1738", "target_type": "compound", "relation": "potential_modulator"},
{"source_id": "H4", "source_type": "hypothesis", "target_id": "JNJ-1935041", "target_type": "compound", "relation": "potential_modulator"},
{"source_id": "H5", "source_type": "hypothesis", "target_id": "CHRM1", "target_type": "gene", "relation": "requires_physical_association"},
{"source_id": "H5", "source_type": "hypothesis", "target_id": "PLA", "target_type": "assay", "relation": "required_for_validation"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "PSD-95", "target_type": "scaffold", "relation": "requires_physical_interaction"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "immunogold_EM", "target_type": "assay", "relation": "required_for_validation"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "Mash1", "target_type": "transcription_factor", "relation": "developmental_regulator"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "Ngn2", "target_type": "transcription_factor", "relation": "developmental_regulator"},
{"source_id": "H6", "source_type": "hypothesis", "target_id": "LYNX1", "target_type": "modulatory_protein", "relation": "requires_differential_binding"},
{"source_id": "H6", "source_type": "hypothesis", "target_id": "LYNX2", "target_type": "modulatory_protein", "relation": "requires_differential_binding"},
{"source_id": "H3", "source_type": "hypothesis", "target_id": "MCT4", "target_type": "transporter", "relation": "metabolic_coupling"},
{"source_id": "H3", "source_type": "hypothesis", "target_id": "GLUT1", "target_type": "transporter", "relation": "metabolic_coupling"}
]
}